SCHEMBL20134835

SCHEMBL20134835

CC(C)C1(c2ccc(C(=O)O)cc2)CC(=O)NC1=O

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 5/20 0.48
RARB P10826 1/20 0.39
RARG P13631 1/20 0.39
CRBN Q96SW2 2/20 0.38
HSD11B1 P28845 1/20 0.37
KMT2A Q03164 1/20 0.37
TP53 P04637 1/20 0.36
TSHR P16473 1/20 0.36
GAA P10253 1/20 0.36
PKM P14618 1/20 0.36
ALDH1A1 P00352 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TDP2 O95551 2/20 0.35
RXRA P19793 2/20 0.35
DDB1 Q16531 1/20 0.35
TAS2R14 Q9NYV8 1/20 0.34
RXRB P28702 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135070 0.80 CYP19A1 (0.63) CYP19A1RARBRARGCRBNHSD11B1
SCHEMBL18492914 0.72 RAMP1 (0.48) RARBRARGCRBNHSD11B1KMT2A
SCHEMBL22791338 0.68 TP53 (0.46) RARBRARGKMT2ATP53TSHR
SCHEMBL20134941 0.68 AKR1B1 (0.40) HSD11B1KMT2ATP53TSHRGAA
SCHEMBL20135221 0.68 AKR1B1 (0.40) HSD11B1KMT2ATP53TSHRGAA
SCHEMBL20134939 0.68 AKR1B1 (0.40) HSD11B1KMT2ATP53TSHRGAA
Terephthalic Acid SCHEMBL23071346 0.65 TSHR (0.75) KMT2ATP53TSHRALDH1A1SMN1; SMN2
Terephthalic Acid SCHEMBL23069370 0.65 TSHR (0.75) KMT2ATP53TSHRALDH1A1SMN1; SMN2
Terephthalic Acid SCHEMBL28393368 0.65 TSHR (0.75) KMT2ATP53TSHRALDH1A1SMN1; SMN2
Terephthalic Acid SCHEMBL4633354 0.65 TSHR (0.57) CRBNTP53TSHRALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 CYP19A1 2754/4885RARB 1594/4885RARG 2147/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 CYP19A1 2331/4885RARB 1308/4885RARG 1742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.